Drugs Containing Excipient (Inactive Ingredient) CALCIUM SILICATE

Branded drugs containing CALCIUM SILICATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HJ Harkins Company Inc	VIRACEPT	nelfinavir mesylate	52959-289	CALCIUM SILICATE
State of Florida DOH Central Pharmacy	VIRACEPT	nelfinavir mesylate	53808-0809	CALCIUM SILICATE
AGOURON	VIRACEPT	nelfinavir mesylate	63010-010	CALCIUM SILICATE

Generic drugs containing CALCIUM SILICATE excipient

Company	Ingredient	NDC	Excipient
Endo USA Inc	felodipine	0603-3581	CALCIUM SILICATE
Sandoz Inc	ziprasidone hydrochloride	0781-2164	CALCIUM SILICATE
Torrent Pharmaceuticals Limited	erythromycin	13668-586	CALCIUM SILICATE
Torrent Pharmaceuticals Limited	erythromycin	13668-606	CALCIUM SILICATE
Camber Pharmaceuticals Inc	dimethyl fumarate	31722-657	CALCIUM SILICATE
Sun Pharmaceutical Industries Inc	carbidopa and levodopa	47335-186	CALCIUM SILICATE

Calcium Silicate Excipient Market Dynamics, Applications, Suppliers, and Financial Trajectory

Last updated: July 31, 2026

Calcium silicate is a low-cost, inorganic pharmaceutical excipient used mainly as an adsorbent, anti-caking agent, flow aid, carrier, and moisture-control material. Its pharmaceutical market is fragmented and materially smaller than its food, feed, construction, ceramics, and industrial desiccant markets. Major suppliers generally do not report calcium silicate revenue separately, so financial analysis depends on market proxies, production economics, regulatory status, and demand from formulated-dose manufacturers.

The commercial outlook is stable rather than high growth. Volume demand should track solid-dose pharmaceutical production, nutraceuticals, powder formulations, and global manufacturing expansion. Price realization is constrained by abundant mineral feedstocks and competition from colloidal silicon dioxide, magnesium aluminometasilicate, calcium phosphate, magnesium stearate, and other functional excipients.

What is calcium silicate and how is it used in pharmaceuticals?

Calcium silicate is an inorganic compound commonly identified by CAS Registry Number 1344-95-2. Its composition can vary with manufacturing method, hydration state, particle structure, calcium-to-silicon ratio, surface area, and impurity profile.

In pharmaceutical formulations, calcium silicate is used for:

Function	Pharmaceutical application
Adsorbent	Converts oils, liquids, and low-viscosity actives into free-flowing powders
Anti-caking agent	Reduces agglomeration in powders and granules
Flow aid	Improves powder handling and die filling
Carrier	Supports liquid or poorly flowing active ingredients
Moisture control	Reduces exposure of hygroscopic formulations to water
Processing aid	Supports blending, granulation, and powder transfer
Bulking or structural aid	Used in selected solid-dose formulations

The material is particularly relevant when a formulation contains a liquid active, volatile ingredient, hygroscopic excipient, or low-dose component that requires improved distribution.

Calcium silicate should not be confused with colloidal silicon dioxide, calcium phosphate, magnesium silicate, or silicified microcrystalline cellulose. These materials can compete for similar formulation functions but have different chemistry, regulatory histories, particle properties, and compendial specifications.

What regulatory status does calcium silicate have in the United States?

Calcium silicate is an established food additive and an accepted pharmaceutical excipient in applicable formulations. The U.S. Food and Drug Administration lists calcium silicate in its Inactive Ingredient Database for certain dosage forms and routes, subject to the specific maximum potency and formulation context recorded in the database (FDA, 2024a).

Its regulatory status is not equivalent to active-ingredient approval. An excipient does not receive an independent NDA approval for a general set of pharmaceutical uses. Instead, the finished product sponsor must demonstrate that the selected grade is suitable for the proposed formulation, dosage form, route of administration, and manufacturing process.

Key U.S. regulatory considerations include:

• FDA Inactive Ingredient Database precedent
• United States Pharmacopeia-National Formulary compliance where applicable
• Identity, purity, loss on drying, heavy metals, elemental impurities, and microbial controls
• Supplier qualification and change-control procedures
• Extractables and leachables assessment where relevant
• Particle-size and surface-area controls
• Documentation under current good manufacturing practice requirements

The FDA IID is important because prior use can reduce regulatory friction. It does not eliminate the need for product-specific justification, especially when a sponsor uses a higher concentration, new route, new dosage form, or materially different grade.

What is the European regulatory status of calcium silicate?

Calcium silicate is recognized in Europe as food additive E552. Food-additive authorization does not automatically establish authorization for every pharmaceutical use, but it provides a substantial toxicological and manufacturing history for the substance.

European pharmaceutical acceptance depends on:

• Compliance with the relevant European Pharmacopoeia or applicable specification
• Quality-by-design assessment
• Control of elemental impurities under ICH Q3D
• Route-specific safety evaluation
• Supplier qualification
• Consistency of particle morphology and surface chemistry
• Compliance with EU good manufacturing practice expectations

The European Medicines Agency’s excipient guidance requires sponsors to provide appropriate quality, safety, and functional information for excipients used in medicinal products (EMA, 2016). The regulatory burden is generally lower for well-established oral excipient uses than for inhalation, parenteral, ophthalmic, or implantable applications.

How large is the calcium silicate pharmaceutical excipient market?

There is no consistently reported, audited global revenue figure for pharmaceutical-grade calcium silicate alone. Public market reports frequently combine calcium silicate with broader categories such as specialty silicates, mineral excipients, food additives, desiccants, or pharmaceutical excipients. Those categories are not interchangeable.

The addressable market is best viewed through four layers:

Market layer	Relative commercial scale	Main demand drivers
Industrial calcium silicate	Very large	Insulation, construction, ceramics, refractories
Food and feed calcium silicate	Large	Anti-caking and flow control
Nutraceutical and cosmetic grades	Moderate	Powders, supplements, topical products
Pharmaceutical excipient grade	Smaller	Tablets, capsules, granules, adsorbent systems

Pharmaceutical-grade demand is constrained by the fact that calcium silicate is usually a functional additive rather than a high-loading primary excipient. A formulation may use a small percentage of the material, and many products can substitute other flow aids or adsorbents.

Its value is therefore driven more by grade qualification and technical performance than by raw material scarcity. High-purity, low-heavy-metal, low-moisture, tightly controlled grades can command a premium over industrial material, but the premium is limited by substitution.

What is driving calcium silicate excipient demand?

Which pharmaceutical trends support growth?

Demand has several durable drivers:

1. Growth in generic solid oral dosage manufacturing.
2. Increased use of direct compression and dry granulation.
3. Expansion of nutraceutical and over-the-counter powder products.
4. Formulation of poorly flowing and hygroscopic active ingredients.
5. Outsourcing of development and manufacturing to contract development and manufacturing organizations.
6. Increased use of low-cost excipients in emerging pharmaceutical markets.
7. Need for improved powder transport, storage, and automated dose manufacturing.

Direct compression is especially relevant because manufacturers seek consistent flow, bulk density, and die-filling performance. Calcium silicate can support these requirements when its particle-size distribution and surface area are controlled.

What limits market expansion?

The main constraints are:

• Substitution by colloidal silicon dioxide
• Substitution by magnesium aluminometasilicate
• Low unit value relative to formulation-development cost
• Limited differentiation among commodity grades
• Qualification costs for new suppliers
• Variation in hydration state and morphology
• Concerns over elemental impurities and batch consistency
• Limited use in parenteral and other high-sensitivity dosage forms

Formulators often select excipients based on established supplier history, regulatory documentation, and process robustness. A lower-cost calcium silicate grade may not displace an incumbent excipient if it requires extensive stability, dissolution, and process validation work.

Which companies supply calcium silicate for pharmaceutical and adjacent markets?

The supply chain includes mineral processors, specialty chemical companies, food-additive manufacturers, and excipient distributors. The market is not controlled by a single pharmaceutical excipient company.

Potential supplier categories include:

• Specialty silicate producers
• Calcium-compound manufacturers
• Inorganic mineral processors
• Food and pharmaceutical excipient distributors
• Regional manufacturers serving generic-drug markets
• Industrial suppliers that produce higher-purity grades for regulated applications

Companies such as Huber Engineered Materials, PQ Corporation, and other global silicate producers participate in adjacent silicate markets, but public disclosures generally do not separate pharmaceutical-grade calcium silicate sales from broader specialty-mineral revenue. Supplier qualification must therefore be based on the specific product grade rather than corporate sector classification.

A pharmaceutical buyer should evaluate:

• GMP and excipient-management systems
• DMF or equivalent regulatory support
• Pharmacopoeial compliance
• Batch-to-batch particle-size consistency
• Specific surface area
• Bulk and tapped density
• Moisture content
• Elemental impurity profile
• Microbial limits
• Change-notification commitments
• Geographic redundancy
• Minimum order quantities and lead times

How does calcium silicate compare with competing pharmaceutical excipients?

Attribute	Calcium silicate	Colloidal silicon dioxide	Magnesium aluminometasilicate	Calcium phosphate
Primary role	Adsorbent and flow aid	Flow aid and anti-caking agent	Adsorbent, flow aid, compactability aid	Diluent and compression aid
Typical cost position	Low to moderate	Moderate	Moderate to high	Low to moderate
Moisture control	Strong	Moderate	Strong	Lower
Liquid adsorption	Strong	Moderate	Strong	Limited to moderate
Direct-compression role	Secondary	Strong	Moderate to strong	Strong
Supplier concentration	Fragmented	More concentrated	Concentrated among specialty suppliers	Fragmented
Regulatory familiarity	Established	Very high	Established	Very high
Substitution risk	High	Moderate	Moderate	High

Calcium silicate has its strongest commercial position when adsorption and moisture control are more important than compactability. It is less differentiated when the formulation only requires improved powder flow.

How strong is the patent estate for calcium silicate?

Calcium silicate is an old, widely known inorganic material. Its basic composition and ordinary pharmaceutical use are unlikely to provide durable exclusivity through a broad composition patent.

Relevant intellectual-property protection is more likely to concern:

• Specific particle morphology
• Porosity or surface-area ranges
• Coated or functionalized particles
• Combination excipient systems
• Controlled-release formulations
• Adsorbent systems for particular active ingredients
• Manufacturing methods that produce a defined grade
• Dosage-form processes using calcium silicate

The commercial barrier is therefore primarily technical and regulatory. A supplier with validated performance data, consistent mineral processing, global quality systems, and a long change-control history may have a stronger market position than a supplier with a broad but difficult-to-enforce patent.

No standard Orange Book exclusivity structure applies to calcium silicate as an excipient. Calcium silicate is not an FDA-approved active ingredient with standalone NCE, orphan-drug, or biologic exclusivity.

Are there Paragraph IV challenges or Orange Book listings for calcium silicate?

Calcium silicate itself does not have an Orange Book listing as an active pharmaceutical ingredient. Paragraph IV litigation generally applies to abbreviated new drug applications that challenge patents listed for a reference listed drug. Because calcium silicate is an excipient, not the active ingredient in a reference drug, there is no standalone Paragraph IV challenge framework for the material.

Litigation can still arise around a finished product that contains calcium silicate, particularly where a formulation, manufacturing process, delivery system, or method of use is patent-protected. Those disputes attach to the drug product and patent claims, not to calcium silicate as a commodity excipient.

What manufacturing and intellectual-property barriers affect supply?

The main manufacturing barriers are process-control requirements rather than raw material access. Important variables include:

• Calcium source purity
• Silica source and reactivity
• Precipitation or solid-state reaction conditions
• Drying temperature and residence time
• Milling and classification
• Porosity
• Surface area
• Residual moisture
• Bulk density
• Trace metals
• Packaging and moisture protection

A manufacturer can produce an industrial calcium silicate product without meeting pharmaceutical-grade expectations. Pharmaceutical supply requires validated cleaning, traceability, controlled change management, analytical release testing, and reliable documentation.

The most important IP opportunities are narrow product and process claims. A differentiated grade with superior liquid-loading capacity, better flow, lower dusting, or improved compression behavior may support customer retention and premium pricing, even if the underlying compound is unpatentable.

What is the financial trajectory for calcium silicate suppliers?

The financial profile is driven by volume, energy costs, logistics, and grade mix.

Financial variable	Expected effect on suppliers
Energy prices	Pressure on margins because drying and processing can be energy-intensive
Mineral and silica feedstock costs	Usually manageable but regionally variable
Freight costs	Important because calcium silicate has a relatively low value-to-weight ratio
Pharmaceutical-grade mix	Improves price and margin realization
Food and industrial exposure	Adds volume but increases commodity-price sensitivity
Supplier qualification	Supports retention once a grade is validated
Capacity utilization	Strong effect on fixed-cost absorption
Regional manufacturing	Reduces freight and supply risk
Regulatory documentation	Raises entry costs and supports customer stickiness

The likely trajectory is moderate volume growth with limited pricing power. Pharmaceutical demand can produce higher margins than industrial sales, but the pharmaceutical segment is unlikely to dominate the financial results of diversified calcium silicate producers unless a supplier develops a specialized high-performance grade.

A supplier’s financial performance should be assessed through specialty-minerals revenue, gross-margin trends, capacity additions, acquisition activity, and exposure to construction and industrial markets. Calcium silicate-specific revenue is generally unavailable in public filings.

What generic launch risks are associated with calcium silicate?

Calcium silicate does not create the main generic-entry barrier for most finished drugs. Generic launch risk is usually determined by:

• Active-ingredient patents
• Formulation patents
• Method-of-use patents
• Bioequivalence requirements
• Dissolution profile
• Manufacturing-process reproducibility
• Device or delivery-system claims
• Regulatory exclusivity

Calcium silicate can affect launch timing indirectly if it is critical to a formulation’s stability or bioequivalence. A generic manufacturer may need to reproduce the functional performance of the reference product without using the same supplier, grade, or process. This can create development work, but it is rarely a standalone legal barrier.

What licensing deals and settlement agreements affect the market?

There is no widely recognized licensing or patent-settlement market specific to calcium silicate as a pharmaceutical excipient. Commercial arrangements are more likely to involve:

• Long-term supply agreements
• Private-label excipient distribution
• Regional manufacturing rights
• Technical-transfer agreements
• Formulation-development partnerships
• Dual-source qualification
• Quality and change-control commitments

Settlement agreements may arise in finished-drug litigation involving formulations that contain calcium silicate, but those agreements generally do not establish an industry-wide exclusivity period for the excipient.

What is the geographic outlook for calcium silicate demand?

Asia-Pacific is likely to remain the largest volume region because of its pharmaceutical manufacturing base, generic-drug production, food processing, and industrial mineral capacity. India and China are particularly important for finished-dose manufacturing and excipient demand.

North America and Europe offer higher value per kilogram because buyers place greater emphasis on regulatory documentation, quality systems, supply continuity, and pharmacopoeial compliance. Latin America, the Middle East, and Southeast Asia provide growth opportunities through expanding generic and consumer-health manufacturing.

Regional supply risks include:

• Dependence on imported specialty grades
• Port and freight disruption
• Local variation in excipient regulation
• Currency volatility
• Limited availability of qualified alternate suppliers
• Differences in pharmacopoeial acceptance

Key Takeaways

• Calcium silicate is an established inorganic excipient used mainly for adsorption, flow control, anti-caking, and moisture management.
• Its pharmaceutical market is smaller than its food, feed, construction, and industrial markets.
• Public companies generally do not disclose calcium silicate pharmaceutical revenue separately.
• Market growth should track solid-dose pharmaceutical production and nutraceutical demand rather than innovation in the excipient itself.
• Substitution from colloidal silicon dioxide, magnesium aluminometasilicate, and calcium phosphate limits pricing power.
• Regulatory qualification, particle control, GMP documentation, and supply reliability are more important than broad composition patents.
• Calcium silicate has no standalone Orange Book exclusivity or Paragraph IV litigation framework.
• Financial upside is strongest for suppliers selling high-purity, tightly controlled, pharmaceutical-grade products rather than commodity material.
• Generic-launch risk is indirect and usually arises from the finished drug’s formulation, process, or method-of-use patents.
• Asia-Pacific is the main volume-growth region, while North America and Europe support premium-grade demand.

FAQs

Is calcium silicate safe as a pharmaceutical excipient?

Calcium silicate has an established history in food and pharmaceutical applications. Safety depends on grade purity, particle properties, route of administration, concentration, and finished-product exposure.

What is the difference between calcium silicate and colloidal silicon dioxide?

Calcium silicate contains calcium and silicon in an inorganic silicate structure. Colloidal silicon dioxide is highly dispersed silicon dioxide. Both can improve powder flow, but calcium silicate generally has stronger liquid-adsorption and moisture-control characteristics.

Can calcium silicate be used in injectable drugs?

Injectable use requires a separate route-specific safety and quality assessment. Established oral-excipient use does not automatically support parenteral use.

Does calcium silicate improve tablet compression?

It can improve powder handling and, in selected formulations, support compression indirectly. Its primary value is adsorption and flow control rather than acting as a high-performance tablet diluent.

How should pharmaceutical companies qualify a calcium silicate supplier?

Qualification should cover identity, purity, particle-size distribution, surface area, density, moisture, elemental impurities, microbial quality, GMP controls, change notification, supply continuity, and performance in the target formulation.

References

1. European Medicines Agency. (2016). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.

2. U.S. Food and Drug Administration. (2024a). Inactive Ingredient Database. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024b). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Part 211.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

5. European Commission. (2024). Food additives database: E552 calcium silicate. European Commission.

6. International Council for Harmonisation. (2019). ICH Q3D(R2): Guideline for elemental impurities. ICH.